A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer

Phase II Study of Dasatinib (BMS-354825) for Advanced 'Triple-negative' Breast Cancer

This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.

Inclusion Criteria:

• females, 18 or older
• recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer
• paraffin-embedded tissue block must be available
• measurable disease
• prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting)
• 0, 1 or 2 chemotherapies in the metastatic setting
• adequate organ function

Exclusion Criteria:

• Metastatic disease confined to bone only
• Symptomatic CNS metastasis
• Concurrent medical condition which may increase the risk of toxicity
• Unable to take oral medication